Litigation Details for CELGENE CORPORATION v. APOTEX INC. (D.N.J. 2018)
✉ Email this page to a colleague
CELGENE CORPORATION v. APOTEX INC. (D.N.J. 2018)
Docket | ⤷ Try a Trial | Date Filed | 2018-11-20 |
Court | District Court, D. New Jersey | Date Terminated | 2019-02-07 |
Cause | 15:1126 Patent Infringement | Assigned To | Esther Salas |
Jury Demand | None | Referred To | Michael A. Hammer |
Patents | 9,993,467 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in CELGENE CORPORATION v. APOTEX INC.
Details for CELGENE CORPORATION v. APOTEX INC. (D.N.J. 2018)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2018-11-20 | 1 | expiration of United States Patent No. 9,993,467 (the “’467 patent” or “the patent-in-suit”) owned by Celgene… 1. This is an action for patent infringement under the patent laws of the United States, 35 … The Patent-in-Suit 4. On June 12, 2018, the United States Patent and Trademark…of the ’467 patent, constitutes infringement of one or more of the claims of that patent under 35 U.S.C… 9 any claim of the patent-in-suit, until after the expiration of the patent-in-suit, or any later | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |